Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Stryker Q3 2026 Results: Net Income $753M, Down 12.3% YoY

Stryker reported net sales of $6,520 million for the third quarter of 2026, a 7.6% increase over the prior year, though net earnings decreased to $753 million due to higher operating expenses and impairment charges. The company reorganized its Orthopaedics segment to form the Ortho Tech business, combining its orthopaedic instruments and Mako portfolios to streamline innovation.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue6,520.06,057.0
Gross profit4,248.03,852.0
Profit before tax997.01,029.0
Net income753.0859.0
EPS (diluted, $ a share)$1.96$2.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-12.3%
Revenue, year on year+7.6%
Gross margin65.2%
Operating margin15.9%
Source

10-Q filed with the SEC, NYSE: SYK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Stryker Corp: key numbers

Share price
$310.72Close, Nov 16
Market cap
$118B
Shares outstanding
380.69MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Stryker Corp

All →
4:31 PM ET Form 4
Insider Selling

Stryker Insider Ronda E. Stryker Sells $179M of Stock

Ronda E. Stryker sold 550,000 shares of Stryker Corp at $323.19 to $327.69 a share (average $325.32) in 6 transactions, worth $179M in total on Nov 6, 2026. Shares held after the trade: 1,701,375 (-0.6%).

Value
$179M
Shares
550,000
Average price
$325.32
Holding change
-0.6%
Trade date
Nov 6, 2026
4:17 PM ET 8-K
Leadership Change

Stryker Leadership Change

Stryker Corporation has increased its board size from 11 to 12 and elected James E. Davis as a new independent director, effective January 1, 2027. Mr. Davis currently serves as the Chairman, CEO, and President of Quest Diagnostics and brings extensive experience from GE Healthcare and McKinsey & Company. He will receive compensation consistent with the company's existing non-employee director pay structure.

Counterparty
James E. Davis
4:11 PM ET 8-K
Financial Results

Stryker Financial Results

Stryker reported Q3 2026 net sales of $6.5 billion, representing 7.7% organic growth, though management noted performance fell slightly short of internal expectations. The company also announced a $3.0 billion increase to its share repurchase program and updated its full-year 2026 guidance.

Term
Q3 2026

“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter. While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.”

Kevin A. Lobo, Chair and CEO
8:09 AM ET 8-K
Leadership Change

Stryker Leadership Change

Stryker announced a planned leadership succession where Kevin Lobo will resign as CEO on December 31, 2026, and transition to Executive Chair of the Board. Spencer Stiles, the current President and COO, has been appointed to succeed Lobo as CEO and will join the Board of Directors effective January 1, 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.